EpCAM: A new therapeutic target for an old cancer antigen

Cancer Biology and Therapy

Volumn 2, Issue 4, 2003, Pages 320-325

  Armstrong, Andrew ^a   Eck, Stephen L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

Author keywords

Colon cancer; EpCAM; GA733 2; Immunotherapy; Monoclonal antibodies

Indexed keywords

CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

CLINICAL TRIAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 12344289903     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.4.451     Document Type: Review

References (61)

1. Dyer, MJ. The Role of CAMPATH-1 Antibodies in the treatment of lymphoid malignancies. Sem Oncol 1999; 26 (5) Suppl 14:52-6.
2. Leonard JP, Coleman M, Schuster MW et al. Immunotherapy of NHL with Epratuzumab (anti-CD22 monoclonal antibody): Excellent tolerability with objective responses. Proc Am Soc Clin Oncol 2000; 19:17a (abstr)
3. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first remission. J Clin Oncol 2001; 19(13):3244-54. (Pubitemid 32591442)
4. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20:3545-57.
5. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Exp Op Biol Ther 2001; 1:719-32. (Pubitemid 33769082)
6. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998; 16:2825-33. (Pubitemid 28363048)
7. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17:98a (abstr).
8. Cobleigh, MA, Vogel CL, Tripathy D. Multinational study of the efficacy and safety of humanized Anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48. (Pubitemid 29415219)
9. Ross, JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16:413-28. (Pubitemid 28524507)
10. Maloney DG. Monoclonal Antibodies in lymphoid neoplasia: Principles for Optimal Combined Therapy. Sem Hemat 2000; 37 (4) Suppl 7:17-26.
11. Coiffier B, LePage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346:235-42. (Pubitemid 34438862)
12. Cheson BD. CHOP plus Rituximab--balancing facts and opinion. N Engl J Med 2002; 346:280-2. (Pubitemid 34438869)
13. Herlyn M, Steplewski Z, Herlyn D, et al. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76:1438-42. (Pubitemid 9136880)
14. Ross A, Herlyn, D, Liopouls D, et al. Isolation and characterizaton of a carcinoma-associated antigen. Biochem and Biophys Res Comm 1986; 135:297-303.
15. Edwards DP, Grzyb KT, Dressler LG, et al. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 1986; 46:1306-17. (Pubitemid 16048272)
16. Spurr NK, Durbin H, Sheer D, et al. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer 1986; 38: 631-636. (Pubitemid 17189119)
17. Bumol T, Marder P, de Herdt S, et al. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. Hybridoma 1988; 7:407-15.
18. Litvinov S, Velders M, Bakker H, et al. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994; 125:437-46. (Pubitemid 24135956)
19. Momberg F, Moldenhauer G, Hammerling G, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific glycoprotein in normal and malignant tissues. Cancer Res 1987; 47:2883-91. (Pubitemid 17113431)
20. Szala S, Foehlich M, Scollon M, et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA1990; 87:3542-6.
21. Linnenbach AJ, Seng BA, Wu S, et al. Retroposition in a family of carcinoma-associated antigen genes. Mol And Cell Biol 1993; 13:1507-15. (Pubitemid 23068088)
22. Chong JM, Speicher DW. Determination of disulfide bond assignments and n-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO171A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem 2001; 276:5804-13.
23. Balzar M, Winter M, de Boer C, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999; 77:699-712.
24. Thampoe I, Ng J, Lloyd K. Biochemical analysis of a human epithelial surface antigen: differential cell expression and processing. Arch Biochem Biophys 1988; 267: 342-352. (Pubitemid 19001035)
25. Denda-Nagai K, Irimura T. MUC1 in carcinoma-host interactions. Glycoconj J 2000; 17:649-58. (Pubitemid 32480350)
26. Irimura T, Denda K, Iida S, et al. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity. J Biochem 1999; 126:975-85. (Pubitemid 30014441)
27. Ripani E, Sacchietti A, Corda D et al. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76:671-6. (Pubitemid 28243939)
28. Tsujikawa M, Kurahashi H, Tanaka T et al. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nature Genetics 1999; 21:420-3. (Pubitemid 29159581)
29. Balzar M, Bakker HA, Briare-de-Bruijn IH et al. Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Mol Cell Biol 1998; 18(8):4833-43. (Pubitemid 28343067)
30. Trebak M, Begg GE, Chong JM et al. Oligomeric state of the colon carcinoma-associated glycoprotein GA733-2 (Ep-CAM/EGP40) and its role in GA733 mediated homotypic cell-cell adhesion. J Biol Chem 2001; 276:2299-309. (Pubitemid 32109716)
31. Bergsagel PL, Victor-Kobrin C, Timblin C, Timblin CR et al. A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells. J Immunol 1992; 148:590-6.
32. Gires O, Kieu C, Fix P et al. Tumor necrosis Factor a negatively regulates the expression of the carcinoma-associated antigen Epithelial Cell Adhesion Molecule. Cancer 2001; 92: 620-628. (Pubitemid 32735198)
33. Gastl G, Spizzo G, Obrist P et al. Ep-CAM over-expression in breast cancer as a predictor of survival. Lancet 2000; 356: 1981-2.
34. Litvinov SV, van Driel W, van Rhijn CM et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Path 1996; 148:865-75. (Pubitemid 126660678)
35. Piyathilake CJ, Frost AR, Weiss H et al. The Expression of Ep-CAM (17-1A) in squamous cell Cancers of the lung. Hum Pathol 2000; 31:482-7. (Pubitemid 30262871)
36. Schiechl H, Dohr G, Eherer A. Immunohistochemical localization and characterization of a protein from the basolateral membrane of rat small intestine epithelium using monoclonal antibody GZ-1. J Histochem Cytochem 1986; 34:1659-65. (Pubitemid 17177620)
37. Sears HF, Mattis J, Herlyn D et al. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 762-5. (Pubitemid 12192184)
38. Sears HF, Herlyn D, Steplewski Z et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Mod 1984; 3:138-50. (Pubitemid 14114011)
39. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79:4761-5.
40. Herlyn D, Sears HF, Ernst CS et al. Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma. Am J Clin Oncol 1991; 14:371-8.
41. Mosolits S, Harmemerg U, Ruden U et al. Autoantibodies against the tumor-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 1999; 47:315-20. (Pubitemid 29151830)
42. Steplewski Z, Lubeck M, Koprowski H et al. Human macrophages armed with murine immunoglobulin G2a antibodies to tumours destroy human cancer cell lines. Int J Cancer 1984; 33:465-8.
43. Fogler W, Klinger M, Abraham K et al. Enhanced cytotoxicity against colon carcinoma by combinations of non-competing monoclonal antibodies to the 17-1A antigen. Cancer Res 1988; 48:6303-8.
44. Fagerberg J, Hjelm A, Ragnhammar P et al. Tumor regression in monoclonal antibody-treated patients correlated with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995; 55:1824-7.
45. Herlyn D, Wattendorff M, Schmoll E, et al: Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 84: 8055-8059
46. Fagerberg J, Ragnhammar P, Liljefors M et al. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996; 42:81-7.
47. Frodin J, Faxas M, Hagstrom B et al. Induction of anti-idiotypic (Ab2) and anti-anti-idiotypic (Ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (Ab1). Relation to the clinical outcome--an important antitumoral effector function? Hybridoma 1991; 10:421-9.
48. Cheung NV, Cheung IY, Canete A et al. Antibody response to murine anti-Gd2 monoclonal antibodies: correlation with patient survival. Cancer Res 1994; 54:2228-33.
49. Reithmuller G, Schnerider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343:1177-83. (Pubitemid 24147551)
50. Riethmuller G, Schlimok G, Schmeigel W, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16:1788-94.
51. Nossal GJ. Minimal residual disease as the target for immunotherapy of cancer. Lancet 1994; 343: 1172-3.
52. Haller DG. Update of Clinical Trials with Edrecolomab: A monoclonal antibody therapy for colorectal cancer. Sem Oncol 2001; 28(1) Suppl 1:25-30. (Pubitemid 32173101)
53. Punt CJ, Nagy A, Douillard J, et al. Edrecolomab (17-1A Antibody) alone or in combination with 5-Fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:123a(abstr).
54. Helfrich W, Kroesen B, Roovers R, et al. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 1998; 76:232-9.
55. Houba PHJ, Boven E, Meulen-Muileman IH, et al. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody b-glucuronidase conjugate. Int J Cancer 2001; 91:550-4.
56. Meyaard L, deVries A, Ruiter T, et al. The Epithelial Cellular Adhesion Molecule (Ep-CAM) is a ligand for the Leukocyte-Associated Immunoglobulin-like Receptor (LAIR). J Exp Med 2001;194:107-12. (Pubitemid 32660442)
57. Meyaard L, Adema GJ, Chang C, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997; 7: 283-290. (Pubitemid 27392019)
58. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875-904. (Pubitemid 29241142)
59. Ravetch J, Lanier L. Immune inhibitory receptors. Science 2000; 290:84-9.
60. Naundorf S, Preithner S, Mayer P et al. In vitro and in vivo activity of MT201, a fully monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002; 100:101-10.
61. Li W, Berencsi K, Basak S et al. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol 1997; 159:763-9. (Pubitemid 127484227)